QDEL

AI Memo

QuidelOrtho

As of 2026-09-03/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Post-Q2 execution checkpoint • 2026-11-05

Base target: $15 / p=45% prob

Biggest risk

The company materially reduced 2026 revenue, EBITDA, and adjusted EPS guidance and withdrew free-cash-flow guidance. China, respiratory demand, working capital, and leverage remain unresolved, while post-earnings reaction was negative.

Invalidation

Break below $10 or thesis failure.

What would change my mind?

Q2 showed resilient ex-China performance, 16% Point of Care growth, and improved adjusted EBITDA margin. If respiratory demand stabilizes, China pricing uncertainty clears, and cash conversion improves, the low share price and approximately $14.67 median target imply modest recovery potential.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-03

Base target

$15

p=45%

Bull target

$19

p=20%

Bear target

$10

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

China and respiratory weakness remain downside triggers
Portfolio execution and deleveraging
Q2 showed resilient ex-China performance, 16% Point of Care growth, and improved adjusted EBITDA margin.

BearKey bullets

A softer respiratory environment could weaken seasonal demand and product adoption.
Analyst coverage and revision data are limited, reducing confidence in valuation signals.
China IVD pricing changes may continue to disrupt purchasing and revenue.

WatchKey bullets

Post-Q2 execution checkpoint

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $15 (p=45%)

Target spread vs base: +27% / -33%

Scenario probabilities

Bull Target: $19 (p=20%)Base Target: $15 (p=45%)Bear Target: $10 (p=35%)

Commentary

Recent coverage is mixed-to-negative: Q2 exceeded stored revenue and adjusted-EPS estimates, but the company cut guidance and withdrew free-cash-flow guidance, followed by a negative market reaction. Social, options, short-interest, and employee-sentiment data are unavailable; low coverage limits confidence.

As of 2026-09-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

China and respiratory weakness remain downside triggers
Portfolio execution and deleveraging

Scenarios

Bull Target (Scenario probability)

$19 / p=20% prob

Base Target (Scenario probability)

$15 / p=45% prob

Bear Target (Scenario probability)

$10 / p=35% prob

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.55

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-05
Post-Q2 execution checkpoint
Q2 revenue grew 3% reported, adjusted EBITDA margin improved to 20.5%, and Point of Care revenue grew 16%, but investors must assess whether ex-China growth and cost actions can offset respiratory and China weakness [#SEC-8K-2026-08-06].
Prob 65.00% • Move 8.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

China and respiratory weakness remain downside triggers
2026-09-30
Management attributed pressure to China IVD pricing uncertainty and a softer global respiratory environment; full-year revenue and earnings guidance were reduced and free-cash-flow guidance withdrawn [#SEC-8K-2026-08-06].
Prob 75% • Move -12% • Priced-in 70%

Long-term Catalysts

Months to a year

Portfolio execution and deleveraging
2027-09-03
Longer-term upside depends on sustained core-franchise growth, respiratory-season execution, working-capital improvement, and leverage reduction; the evidence remains early and unproven.
Prob 45% • Move 20% • Priced-in 25%

Risks

A softer respiratory environment could weaken seasonal demand and product adoption.
Analyst coverage and revision data are limited, reducing confidence in valuation signals.
China IVD pricing changes may continue to disrupt purchasing and revenue.
GAAP losses and execution risk remain despite improved adjusted EBITDA margin.
Reduced guidance and withdrawn free-cash-flow guidance increase cash-conversion and leverage uncertainty.

Peers

Symbol	Summary
ABT	Diagnostics-oriented but far more diversified and scaled; comparison highlights QDEL's greater execution, margin, and balance-sheet risk.
BSX	Broader medtech rather than a direct diagnostics peer; its stronger growth profile underscores the need for QDEL to prove durable product-cycle and margin improvement.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-03

Loading AI feed…

Symbol

Summary

ABT

Diagnostics-oriented but far more diversified and scaled; comparison highlights QDEL's greater execution, margin, and balance-sheet risk.

BSX

Broader medtech rather than a direct diagnostics peer; its stronger growth profile underscores the need for QDEL to prove durable product-cycle and margin improvement.